DOI: 10.36347/sjams.2016.v04i11.028

Pages: 3996-3999

The objective of this study is to compare the efficacy as well as safety profile of Hydralazine and Labetalol in severe pregnancy induced hypertension. 100 women with severe pregnancy induced hypertension were randomly allocated into two groups of 50 each. Study group was given intravenous hydralazine and control group was treated with labetalol. The efficacy of the two drugs were noted in terms of time taken to achieve target blood pressure, number of doses required and number of patients developing severe persistent hypertension. The adverse effects of the two drugs and the perinatal outcome were also noted. There were no statistical difference between the two drugs in terms of efficacy, perinatal outcome and adverse effects except headache which was significantly more in hydralazine group. Both hydralazine and labetalol can be used to treat hypertensive emergencies and there is no significant difference between the two drugs.